EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Berbamine hydrochloride as a brain-penetrant galectin-3 inhibitor in a model of Huntington’s disease

Jian Jing Siew iD, Chia-Wei Lee, Hui-Mei Chen, Hsien-Ya Lin, Yi-Ling Liu, Yi-Hsuan Lee, Ying-Ta Wu, Hung-Lin Chen, Fu-Tong Liu, Chun-Hung Lin, Yijuang Chern iD

Brain · 05.10.2026 · 149 (10) · 3414-3430

DOI: 10.1093/brain/awag069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 03.03.2026. Verfasst von Jian Jing Siew und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan. Hauptthemen laut MEDLINE: Huntington Disease, Galectin 3, Brain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academia Sinica and Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Galectin-3 (Gal3) acts as an intracellular sensor of lysosomal damage and a key driver of microglial activation and neuroinflammation in multiple neurodegenerative disorders. Despite its biological importance, no inhibitors have been identified that both modulate intracellular Gal3 activity and effectively cross the blood–brain barrier. Here, we established an innovative high-content imaging platform using microglia expressing Gal3-GFP, allowing direct visualization of Gal3 puncta formation upon lysosomal damage as a phenotypic readout for compound screening. Through screening of ∼24 000 small molecules, we identified berbamine hydrochloride as a potent inhibitor of Gal3 puncta formation with confirmed blood–brain barrier permeability. Mechanistically, berbamine hydrochloride disrupts Gal3 oligomerization and Gal3–TREM2 interaction via a unique allosteric mechanism distinct from the canonical glycan-binding domain. It attenuated lipopolysaccharide-induced inflammation in vitro and achieved sustained brain exposure in vivo. In the R6/2 mouse model of Huntington’s disease, berbamine hydrochloride effectively improved motor functions, reduced mutant huntingtin protein aggregation and restored crucial dopaminergic and ciliary signalling pathways. Transcriptomic profiling further identified Gal3 as a central regulatory hub within Huntington’s disease-associated networks that were corrected upon treatment. Computational docking and molecular dynamics simulations further supported an allosteric binding mode distinct from the canonical glycan-binding domain of Gal3. Together, these findings establish berbamine hydrochloride as the first blood–brain barrier-penetrant small molecule inhibitor targeting intracellular Gal3 with therapeutic benefit in Huntington’s disease. Furthermore, the puncta-based screening strategy that we developed provides a robust platform for discovering intracellular modulators of Gal3 relevant to a wide range of neurological diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseGalectin 3BrainAnimalsMiceDisease Models, AnimalHumansMice, TransgenicBlood-Brain BarrierMicrogliaBenzylisoquinolines

Stichwörter der Autor:innen

Huntington’s diseasedrug screeninggalectinmicroglianeurodegeneration

Substanzen

Galectin 3berbamineBenzylisoquinolines

Autor:innen und Institutionen

  • Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
  • Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan.
  • Genomics Research Center, Academia Sinica, Taipei 115, Taiwan.
  • Department and Institute of Physiology, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
  • Brain Research Center, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
  • Master Program in Clinical Genomics and Proteomics, Taipei Medical University, Taipei 110, Taiwan.

ORCID-Profile: Jian Jing Siew, Yijuang Chern

Förderung

  • Academia Sinica and Ministry of Science and Technology, Taiwan

Zitieren

APA

Siew, J. J., Lee, C. W., Chen, H. M., Lin, H. Y., Liu, Y. L., Lee, Y. H., Wu, Y. T., Chen, H. L., Liu, F. T., Lin, C. H., & Chern, Y. (2026). Berbamine hydrochloride as a brain-penetrant galectin-3 inhibitor in a model of Huntington’s disease. Brain, 149(10), 3414-3430. https://doi.org/10.1093/brain/awag069

Vancouver

Siew JJ, Lee CW, Chen HM, Lin HY, Liu YL, Lee YH, et al. Berbamine hydrochloride as a brain-penetrant galectin-3 inhibitor in a model of Huntington’s disease. Brain. 2026;149(10):3414-3430. doi:10.1093/brain/awag069

BibTeX
@article{Siew2026,
  author = {Siew, Jian Jing and Lee, Chia-Wei and Chen, Hui-Mei and Lin, Hsien-Ya and Liu, Yi-Ling and Lee, Yi-Hsuan and Wu, Ying-Ta and Chen, Hung-Lin and Liu, Fu-Tong and Lin, Chun-Hung and Chern, Yijuang},
  title = {Berbamine hydrochloride as a brain-penetrant galectin-3 inhibitor in a model of Huntington’s disease},
  journal = {Brain},
  year = {2026},
  volume = {149},
  number = {10},
  pages = {3414--3430},
  doi = {10.1093/brain/awag069}
}
Kostenlos starten →